The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress.

Szczegóły
Abstrakt

Tytuł:: The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress.
Autorzy:: Dixon SB; Department of Oncology, St. Jude Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA. Electronic address: .
Chow EJ; Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, M4-C308, Seattle, WA 98109, USA.
Hjorth L; Department of Paediatrics, Skane University Hospital, Lund, Sweden; Clinical Sciences Lund, Lund University, Lund 221 85, Sweden.
Hudson MM; Division of Cancer Survivorship, Department of Oncology, St. Jude Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Kremer LCM; Princess Maxima Center, Heidelberglaan 25, Utrecht 3584 CS, Netherlands; Emma Children's Hospital, Amsterdam UMC, Amsterdam, Netherlands.
Morton LM; Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9778, Bethesda, MD 20892-9778, USA.
Nathan PC; Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Room 9402 Black Wing, Toronto, ON M5G 1X8, Canada.
Ness KK; Department of Epidemiology and Cancer Control, St. Jude. Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Oeffinger KC; Duke Center for Onco-Primary Care, Duke Cancer Institute, 2424 Erwin Drive, Suite 601, Durham, NC 27705, USA.
Armstrong GT; Department of Epidemiology and Cancer Control, St. Jude. Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Źródło:: Pediatric clinics of North America [Pediatr Clin North Am] 2020 Dec; Vol. 67 (6), pp. 1237-1251.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Review
Język:: English
Imprint Name(s):: Publication: Philadelphia, PA : W.B. Saunders
Original Publication: Philadelphia.
MeSH Terms:: Cancer Survivors*
Delivery of Health Care/*trends
Medical Oncology/*trends
Neoplasms/*therapy
Biomedical Research ; Continuity of Patient Care ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Radiotherapy/adverse effects
References:: Nat Genet. 2015 Apr;47(4):373-80. (PMID: 25751625)
J Clin Oncol. 2016 Mar 1;34(7):747-55. (PMID: 26786921)
Nat Rev Cancer. 2014 Jan;14(1):61-70. (PMID: 24304873)
J Clin Oncol. 2015 Feb 10;33(5):394-402. (PMID: 25287823)
J Clin Oncol. 2009 May 10;27(14):2308-18. (PMID: 19364948)
J Clin Oncol. 2015 Nov 20;33(33):3887-93. (PMID: 26324371)
J Clin Oncol. 2016 Dec 20;34(36):4381-4389. (PMID: 27998223)
Cancer. 2015 Dec 15;121(24):4389-97. (PMID: 26406998)
J Clin Oncol. 2018 Jul 20;36(21):2206-2215. (PMID: 29874132)
J Clin Oncol. 2018 Jul 10;36(20):2078-2087. (PMID: 29847298)
J Cancer Surviv. 2019 Oct;13(5):713-729. (PMID: 31338733)
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. (PMID: 11253156)
J Adolesc Young Adult Oncol. 2017 Mar;6(1):74-82. (PMID: 27754726)
Acta Oncol. 2015 May;54(5):655-68. (PMID: 25813473)
JAMA. 2013 Jun 12;309(22):2371-2381. (PMID: 23757085)
Lancet. 2018 Mar 10;391(10124):933. (PMID: 29536852)
J Clin Oncol. 2014 Apr 20;32(12):1218-27. (PMID: 24638000)
Proc Biol Sci. 2015 Dec 22;282(1821):20151684. (PMID: 26702037)
Ann Intern Med. 2010 Oct 5;153(7):442-51. (PMID: 20921543)
Lancet. 2017 Dec 9;390(10112):2569-2582. (PMID: 28890157)
J Clin Oncol. 2017 Jul 10;35(20):2288-2298. (PMID: 28530852)
J Clin Oncol. 2018 Jan 1;36(1):44-52. (PMID: 29095680)
J Clin Oncol. 2018 Jul 10;36(20):2088-2100. (PMID: 29775389)
Pediatr Blood Cancer. 2017 Nov;64(11):. (PMID: 28488345)
Trials. 2015 Mar 24;16:109. (PMID: 25873142)
MedGenMed. 2001 Mar 05;3(2):2. (PMID: 11549951)
Pediatr Blood Cancer. 2011 May;56(5):825-36. (PMID: 21370418)
J Natl Cancer Inst. 2020 Mar 1;112(3):256-265. (PMID: 31161223)
Cell. 2013 Jun 6;153(6):1194-217. (PMID: 23746838)
J Clin Oncol. 2020 Jan 1;38(1):29-42. (PMID: 31622133)
JAMA Oncol. 2019 Jun 1;5(6):864-871. (PMID: 30703192)
EBioMedicine. 2017 Jul;21:21-28. (PMID: 28416161)
J Clin Oncol. 2015 Nov 10;33(32):3774-80. (PMID: 26304888)
J Natl Cancer Inst. 2018 Dec 1;110(12):1352-1359. (PMID: 29771337)
J Cancer Surviv. 2018 Oct;12(5):639-646. (PMID: 29943170)
N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870)
Lancet Oncol. 2015 Dec;16(16):1691-9. (PMID: 26549589)
Cancer. 1975 Mar;35(3 suppl):866-70. (PMID: 1089473)
Br J Clin Pharmacol. 2016 Sep;82(3):683-95. (PMID: 27197003)
J Natl Cancer Inst. 2017 Nov 1;109(11):. (PMID: 29059430)
Blood. 2019 Mar 7;133(10):1130-1139. (PMID: 30573632)
J Clin Oncol. 2013 Dec 20;31(36):4496-503. (PMID: 24248696)
Cochrane Database Syst Rev. 2016 Mar 31;3:CD008796. (PMID: 27030386)
J Pediatr. 2011 Oct;159(4):676-81. (PMID: 21592517)
Aging Cell. 2015 Aug;14(4):644-58. (PMID: 25754370)
N Engl J Med. 2016 Aug 25;375(8):740-53. (PMID: 27292104)
PLoS One. 2015 Jun 24;10(6):e0131192. (PMID: 26107505)
J Clin Oncol. 2017 Oct 1;35(28):3215-3221. (PMID: 28787259)
Lancet Oncol. 2018 Dec;19(12):1590-1601. (PMID: 30416076)
Cancer. 2015 Mar 1;121(5):648-63. (PMID: 25355167)
Annu Rev Med. 2018 Jan 29;69:247-262. (PMID: 29029584)
Science. 2019 Mar 15;363(6432):1175-1181. (PMID: 30872517)
Sci Rep. 2017 Dec;7(1):39. (PMID: 28232737)
J Clin Oncol. 2014 Dec 10;32(35):3974-81. (PMID: 25366684)
N Engl J Med. 2010 Sep 30;363(14):1324-34. (PMID: 20879881)
Eur J Cancer. 2018 Oct;102:69-81. (PMID: 30138773)
J Clin Oncol. 2012 Jun 20;30(18):2183-9. (PMID: 22454421)
Patient Educ Couns. 2018 Sep;101(9):1683-1689. (PMID: 29661702)
J Clin Oncol. 2019 Aug 20;37(24):2131-2140. (PMID: 31260642)
JAMA. 2017 Feb 28;317(8):814-824. (PMID: 28245323)
J Clin Oncol. 2009 Nov 1;27(31):5175-81. (PMID: 19805687)
CA Cancer J Clin. 2018 Mar;68(2):133-152. (PMID: 29377070)
PLoS Genet. 2018 Dec 26;14(12):e1007752. (PMID: 30586411)
Health Serv Res. 2015 Aug;50(4):1021-42. (PMID: 25600956)
J Public Health (Oxf). 2018 Dec 1;40(4):e552-e559. (PMID: 29897560)
J Clin Oncol. 2018 Jul 20;36(21):2231-2240. (PMID: 29874142)
Grant Information:: P30 CA021765 United States CA NCI NIH HHS
Contributed Indexing:: Keywords: Adolescent; Cancer; Child; Delivery of health care; Neoplasms; Survivor; Treatment outcome
Entry Date(s):: Date Created: 20201102 Date Completed: 20210111 Latest Revision: 20211203
Update Code:: 20240105
PubMed Central ID:: PMC7773506
DOI:: 10.1016/j.pcl.2020.07.013
PMID:: 33131544
: Czasopismo naukowe

As treatment evolves and the population who survive childhood cancer ages and increases in number, researchers must use novel approaches to prevent, identify and mitigate adverse effects of treatment. Future priorities include collaborative efforts to pool large cohort data to improve detection of late effects, identify late effects of novel therapies, and determine the contribution of genetic factors along with physiologic and accelerated aging among survivors. This knowledge should translate to individual risk prediction and prevention strategies. Finally, we must utilize health services research and implementation science to improve adoption of survivorship care recommendations outside of specialized pediatric oncology centers.
Competing Interests: Disclosure The authors have nothing to disclose.
(Copyright © 2020 Elsevier Inc. All rights reserved.)

Informacja